1 Therapies|Clear filters
Reg. name: Empliciti®
Class: Monoclonal Antibody
Elotuzumab is a humanized monoclonal antibody against human SLAMF7 (signaling lymphocytic activation molecule family member 7) , which is highly expressed on both Multiple Myeloma cells and Natural Killer (NK) cells. Binding of SLAMF7 by elotuzumab is thought to trigger antibody-dependent cellular cytotoxicity (ADCC) in MM cells by a dual mechanism of action: direct activation of NK cells and by tagging the MM cells for recognition by the activated NK cells and subsequent destruction by the degranulation of cytotoxic granules from the activated NK cells. In addition, blocking SLAMF& may block the interaction between MM cells and their adhesion to bone marrow stromal cells (BMSCs).
EMPLICITI® is indicated in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.
|Disease:||Relapsed/refractory patients, Patients eligible for transplant, Patients non-eligible for transplant, Elderly patients, General MM,|
EMPLICITI® is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies.
|Disease:||Relapsed/refractory patients, Elderly patients, General MM,|